Salinomycin abolished STAT3 and STAT1 interactions and reduced telomerase activity in colorectal cancer cells

Anticancer Research

Volumn 37, Issue 2, 2017, Pages 445-454

  Chung, Seyung S ^a,b   Adekoya, Debbie ^a   Enenmoh, Ikechukwu ^a   Clarke, Orette ^a   Wang, Piwen ^a,b   Sarkyssian, Marianna ^a,b   Wu, Yong ^a,b   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cells; MST 312; Salinomycin; STAT1; STAT3; Telomerase

Indexed keywords

BETA CATENIN; CYTOKINE; FLUOROURACIL; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; SALINOMYCIN; STAT1 PROTEIN; STAT3 PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR; UVOMORULIN; VIMENTIN; BENZAMIDE DERIVATIVE; CTNNB1 PROTEIN, HUMAN; MST 312; PYRAN DERIVATIVE; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRESS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST CULTURE; HT-29 CELL LINE; HUMAN; HUMAN CELL; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SW480 CELL LINE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

BENZAMIDES; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; HT29 CELLS; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-6; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PYRANS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TELOMERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85012840852     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11336     Document Type: Article

References (22)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Luu C, Arrington K, Schoellhammer H, Singh G and Kim J: Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 4: 328-336, 2013.
3. Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D, Visvader J, Weissman I and Wahl G: Cancer stem cells-perspectives on current status and future directions. Cancer Res 66: 9339-9344, 2006.
4. Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R and Lander E: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659, 2009.
5. Kim K, Yu S, Lee S, Chun S, Choi Y, Park Y, Song C, Chatterjee B and Ahn S: Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophysical Res Comm 413: 80-86, 2011.
6. An H, Kim J, Oh E, Lee N, Cho Y and Seo J: Salinomycin promotes anoikis and decrease the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLOS One 10: e014919, 2015.
7. Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S, Bloushitain-Quimron N, Choudhury S, Maruyama R, Wu Z, Gonen M, Mulvey L, Bessarabova M, Huh S, Silver S, Kim S, Park S, Lee H, Anderson K, Richardson A, Nikolskaya T, Nikolsky Y, Liu X, Root D, Hahn W, Frank D and Polyak K: The JAK2/STAT3 signaling pathway is required for growth of CD44(+) CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735, 2011.
8. Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C and Vadgama J: Identification of novel biomarkers for metastatic colorectal cancer using angiogenesis-antibody array and intracellular signaling array. PLOS One 10: e0134948, 2015.
9. Dauer D, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R and Haura E: STAT3 regulates genes common both wound healing and cancer. Oncogene 24: 3397-3408, 2005.
10. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsukiya K and Tsuruo T: Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 1: 657-665, 2002.
11. Bertorelle R, Rampazzo E, Pucciarelli S, Nitti D and De Rossi A: Telomeres, Telomerase and Colorectal Cancer. World J Gastroenterol 20: 1940-1950, 2014.
12. Tatsumoto N, Hiyama E, Murakami Y, Imamura Y, Shay J, Matsuura Y and Yokoyama T: High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 6: 2696-2701, 2000.
13. Schwartz H, Juliao S, Sciadini M, Miller L and Burtler M: Telomerase activity in oncogenesis in giant cell tumor of bone. Cancer 75: 1094-1099, 1995.
14. Urquidi V, Tarin D and Goodison S: Role of telomerase in cell senescence and oncogenesis. Annual Rev Med 51: 65-79, 2000.
15. Blasco M and Hahn W: Evolving views of telomerase and cancer. Trend in Cell Biol 13: 289-294, 2003.
16. Stewart S, Hahn W, O'Connor B, Banner E, Lundberg A, Modha P, Mizuno H, Brooks M, Fleming M, Zimonjic D, Popescu N and Weinberg R: Telomerase contribute to tumorigenesis by a telomere length independent mechanism. Proc Nat Acad Sci 99: 12606-12611, 2002.
17. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Bjorkholm M, Jia J and Xu D: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell like traits in cancer cells. Oncogene 32: 4203-4213, 2013.
18. Liu H, Ren G, Wang T, Chen Y, Gong C, Bai Y, Wang B, Qi H, Shen Z, Zhu L, Qian C, Lai M and Shao J: Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis 36: 459-468, 2015.
19. Konnikova L, Simeone M, Kruger M, Kotecki M and Cochran B: Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 65: 6516-6520, 2005.
20. Turkson J and Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000.
21. Kamran M, Patil P and Gude R: Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 2013: 421821, 2013.
22. Gurung R, Lim S, Low G and Hande M: MST-312 alters telomere dynamics, gene expression profiles and growth in human breast cancer cells. J Nutrigenetics and Nutrigenomics 7: 283-298, 2014.